New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
10:56 EDTDBD, HMSY, NRF, NKTR, PQHigh option volume stocks: HMSY PQ NRF DBD NKTR
News For HMSY;PQ;NRF;DBD;NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
09:02 EDTDBDDiebold and Banque Internationale a Luxembourg partner for cardless solution
Subscribe for More Information
December 11, 2014
18:03 EDTNKTRNektar reports data from Phase 3 BEACON study of NKTR-102
Nektar Therapeutics presented biomarker data from a sub-study of the Phase 3 BEACON study of etirinotecan pegol (NKTR-102) which collected and analyzed circulating tumor cell samples from patients in the study. A total of 80% of the 852 patients enrolled in the BEACON trial participated in the CTC sub-study. Among the 627 patients who participated and had evaluable baseline samples, CTCs were detected in 97% of these samples. For the 611 evaluable baseline patient samples which yielded CTCs, potential NKTR-102 target-specific pharmacodynamic biomarkers were detected in the majority of samples. The pharmacodynamic biomarkers assessed in the CTC sub-study were chosen because of their potential ability to predict response to topoisomerase inhibition as well as to measure chemo-sensitivity in metastatic cancer patients
08:05 EDTNKTRFDA Pediatric Oncologic Subcommittee to hold a meeting
Subscribe for More Information
December 10, 2014
08:47 EDTDBDDiebold extends cost reduction initiative into 2016 and 2017
Subscribe for More Information
08:47 EDTDBDDiebold sees FY15 non-GAAP EPS $1.90-$2.10, consensus $2.03
Sees FY15 financial self-service revenue up 2%-4%; Sees FY15 security revenue relatively flat YoY. Sees FY15 Brazil "other" revenue to be approximately $50M. Sees FY15 non-GAAP effective tax rate of approximately 30%. Sees FY15 free cahs flow to be approximately $120M. Sees FY15 negative impact from currency of 1.5%.
08:45 EDTDBDDiebold backs FY14 non-GAAP EPS $1.70-$1.80, consensus $1.77
Subscribe for More Information
08:01 EDTPQCapital One to hold a conference
Subscribe for More Information
07:24 EDTDBDImperial Capital to hold a conference
Subscribe for More Information
December 9, 2014
12:25 EDTPQOn The Fly: Midday Wrap
Subscribe for More Information
08:02 EDTNKTRMoventig approved in EU for opioid-induced constipation
Nektar (NKTR) reported partner AstraZeneca (AZN) announced that MOVENTIG has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative. MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist to be approved in the European Union.
07:44 EDTNKTRAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:33 EDTPQPetroQuest announces significant discovery at Thunder Bayou Prospect
Subscribe for More Information
07:02 EDTPQPetroQuest coverage resumed with a Hold at Stifel
Subscribe for More Information
December 8, 2014
07:29 EDTNKTRUBS to hold investor trip
Subscribe for More Information
07:18 EDTNKTRUBS to hold investor trip
2014 Annual West Coast Investor Trip travels on the West Coast on December 8-10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use